Cancer of the Lung And SeneScencE - Prospective Cohort 1 (CLASSE-P1)

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Non-Small Cell Lung Cancer

Treatments

Biological: Blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT06923618

APHP241246

ID-RCB Number (Other Identifier)

Details and patient eligibility

About

The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve prognosis assessment older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).

Full description

Geriatric assessment allows oncologists to stratify older cancer patients into risk categories (fit, vulnerable and frail) but few patients benefit from it. Yet, they do not evaluate physiological reserves when oncologists are in dire need of quantitative tools accounting for age-related changes. This decade has witnessed the remarkable power of multiple tools (epigenetics, telomere integrity, cellular and immunosenescence) to estimate an individual's age. These tools hold the potential for routine implementation in the clinic and to be combined with existing tests. The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve to improve prognosis assessment in older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).

The ambition of this study is to refine the prognosis assessment and optimize decision-making process, better anticipate adverse-events and unplanned hospitalization and better manage and care high risk patients of early death, unplanned hospitalization, major complication or toxicities and altered quality of life.

Enrollment

385 estimated patients

Sex

All

Ages

70+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients 70 years and over
Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven)
Surgical Curative Intent
Signed informed Consent (or signed by the curator or tutorship)
Affiliated to social security administrative care service

Exclusion criteria

Synchronous cancer (histologically proven or strongly suspected non-lung cancer in the 6 months prior to inclusion (excluding basal cell cancer and prostate cancer with local treatment (radiotherapy or surgery) or active surveillance without systemic treatment (chemotherapy, hormone therapy)).
Subject deprived of liberty by judicial or administrative decision or patient under guardianship
Subject unable to understand the purpose and conditions of the study and unable to give consent